Could the gut be priming the body for a more severe stroke?

Gut microbiota composition may influence ischemic stroke severity by modulating immune responses through the aryl hydrocarbon receptor (AHR) signaling pathway in intestinal dendritic cells. Research using a transient middle cerebral artery occlusion model explored how microbial profiles correlate with stroke outcomes, revealing that severe stroke was associated with changes in ileal microbial diversity, including depletion of certain obligate anaerobes and enrichment of *E. coli*. Fecal microbiota transplantation experiments investigated whether microbial factors from stroke patients influence immune responses via indole metabolites measured in various samples. Administration of indole in mice increased infarct volume and neurological deficits, and this effect correlated with AHR-based responses in dendritic cells. Depleting regulatory T cells (Tregs) reversed the neuroprotective effects observed following AHR inhibition in mice, suggesting Tregs are necessary for protection. Human metagenomic analyses showed enrichment of *E. coli* and *tnaA* in stroke patients, but associations were complex upon adjustment for clinical factors.

The research establishes a complex communication network between the gut microbiome, AHR signaling, intestinal immune cells, and neurological injury severity. The pattern suggests that microbial composition programs intestinal immune responses which subsequently influence systemic inflammation and potential neuroprotection following stroke. The core implication is that gut-brain axis dysfunction may be mediated by microbial metabolic byproducts, such as indole, acting through receptors like AHR to modulate dendritic cell function and T-cell populations (Tregs). The observed necessity of Tregs for the protective effects induced by AHR inhibition suggests a crucial role for regulatory mechanisms in resolving post-stroke inflammation. However, the transition from murine models to human data remains correlative regarding direct causality between microbial tryptophan metabolism and stroke severity. Future research must focus on isolating the causal pathway: determining if microbiome-driven AHR signaling directly programs the immune landscape before physical brain injury occurs, and whether specific microbial metabolites serve as clinically relevant biomarkers or targets for intervention in human stroke susceptibility.